367 related articles for article (PubMed ID: 23361434)
1. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
2. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
[TBL] [Abstract][Full Text] [Related]
3. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
4. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral valaciclovir on herpetic keratitis.
Higaki S; Itahashi M; Deai T; Fukuda M; Shimomura Y
Cornea; 2006 Dec; 25(10 Suppl 1):S64-7. PubMed ID: 17001196
[TBL] [Abstract][Full Text] [Related]
6. Effects of anti herpetic drugs on mice with herpetic epithelial keratitis after reactivation of herpes simplex virus type 1.
Itahashi M; Higaki S; Shimomura Y
Semin Ophthalmol; 2008; 23(4):241-7. PubMed ID: 18584562
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
[TBL] [Abstract][Full Text] [Related]
9. Effects of antiviral medications on herpetic epithelial keratitis in mice.
Komoto S; Higaki S; Fukuda M; Shimomura Y
Jpn J Ophthalmol; 2015 May; 59(3):194-200. PubMed ID: 25707352
[TBL] [Abstract][Full Text] [Related]
10. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
13. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
14. Pediatric herpes simplex virus keratitis.
Hsiao CH; Yeung L; Yeh LK; Kao LY; Tan HY; Wang NK; Lin KK; Ma DH
Cornea; 2009 Apr; 28(3):249-53. PubMed ID: 19387223
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial.
Sozen E; Avunduk AM; Akyol N
Chemotherapy; 2006; 52(1):29-31. PubMed ID: 16340195
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
17. [Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis].
Shimomura Y
Nippon Ganka Gakkai Zasshi; 2008 Mar; 112(3):247-64; discussion 265. PubMed ID: 18411713
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents.
Tsatsos M; MacGregor C; Athanasiadis I; Moschos MM; Hossain P; Anderson D
Clin Exp Ophthalmol; 2016 Dec; 44(9):824-837. PubMed ID: 27273328
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
20. [Battle with herpes for 37 years].
Shimomura Y
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):145-66; discussion 167. PubMed ID: 25854108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
